Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Down 5.95%
As of Thursday, October 08, Aardvark Therapeutics, Inc.’s AARD share price has dipped by 5.95%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Commentary & Analysis
Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Up 6.91%
As of Monday, October 05, Aardvark Therapeutics, Inc.’s AARD share price has surged by 6.91%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Down 5.96%
As of Friday, October 02, Aardvark Therapeutics, Inc.’s AARD share price has dipped by 5.96%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Down 5.79%
As of Friday, September 18, Aardvark Therapeutics, Inc.’s AARD share price has dipped by 5.79%, which has investors questioning if this is right time to buy.Michael Rose
Why Aardvark Therapeutics, Inc.’s (AARD) Stock Is Up 8.93%
As of Thursday, September 17, Aardvark Therapeutics, Inc.’s AARD share price has surged by 8.93%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Financial Summary
| Share Statistics | AARD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $104.2 | $519.2 | 22% |
|
| Shares Out (Mil) | 21.8 | 42.8 | 32% |
|
| Institutional Ownership | 54.9% | 82.8% | 37% |
|
| Float (Mil) | 11.0 | 44.4 | 20% |
|
| Beta | na | 0.71 | na |
|
| Avg Daily Volume (000s) | 131 | 394 | 39% |
|
| Price Change (52-week) |
(72.2%) | 60.2% | 11% |
|
| Growth | AARD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.1% | na |
|
| Net Income (5yr) | na | (2.0%) | na |
|
| EPS (5yr) | na | 15.0% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 8 | 8 | 8 | |
| Current EPS | ($0.748) | ($3.168) | ($2.381) | |
| Month Ago EPS | ($0.772) | ($3.168) | ($2.782) | |
| # Rev Up | 0 | 0 | 0 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($0.869) | ($3.651) | ($3.238) | |
| Year/Year Chg | 13.5% | 7.9% | (17.6%) | |
| Financials | AARD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $416 | na |
|
| Net Income (TTM) (Mil) | ($70) | ($11) | 14% |
|
| EPS (TTM) | ($3.205) | ($0.700) | 11% |
|
| Operating Cash Flow (TTM) (Mil) | ($69) | ($7) | 8% |
|
| Net Cash Flow (TTM) (Mil) | $48 | $6 | 70% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 13% |
|
| Enterprise Value (Q1) (Mil) | $49 | $494 | 16% |
|
| Valuation | AARD | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.39 | 2.31 | 39% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | AARD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 69.4% | na |
|
| Net Margin | na | 3.2% | na |
|
| ROA | (61.1%) | (22.2%) | 10% |
|
| ROE | (66.0%) | (21.4%) | 13% |
|
| Liabilities to Assets | 8.2% | 32.8% | 5% |
|
| F-Score | 2 | 3 | 7% |
|
Aardvark Therapeutics, Inc. did not pass any screens on 10/9/2026.
